Compare Stocks: QURE, KRYS, KYMR, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$66.48 -1.9%	$82.93	$30.25 ▼ $95.49	$9.36B	1.28	1.72 million shs	4.02 million shs
KRYS Krystal Biotech	$336.67 -0.6%	$344.05	$158.08 ▼ $382.54	$9.97B	0.54	231,899 shs	1.00 million shs
KYMR Kymera Therapeutics	$117.75 -0.6%	$114.36	$47.90 ▼ $130.05	$9.79B	1.96	599,332 shs	1.90 million shs
QURE uniQure	$44.00 -0.2%	$44.46	$8.73 ▼ $71.50	$3.05B	0.94	1.13 million shs	2.10 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-19.76%	-24.00%	-18.75%	+128.22%
KRYS Krystal Biotech	0.00%	-2.98%	-0.10%	-3.27%	+118.55%
KYMR Kymera Therapeutics	0.00%	+2.43%	-3.09%	+30.21%	+144.70%
QURE uniQure	0.00%	-1.15%	-10.00%	-4.95%	+210.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$66.48 -1.9%	$82.93	$30.25 ▼ $95.49	$9.36B	1.28	1.72 million shs	4.02 million shs
KRYS Krystal Biotech	$336.67 -0.6%	$344.05	$158.08 ▼ $382.54	$9.97B	0.54	231,899 shs	1.00 million shs
KYMR Kymera Therapeutics	$117.75 -0.6%	$114.36	$47.90 ▼ $130.05	$9.79B	1.96	599,332 shs	1.90 million shs
QURE uniQure	$44.00 -0.2%	$44.46	$8.73 ▼ $71.50	$3.05B	0.94	1.13 million shs	2.10 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-19.76%	-24.00%	-18.75%	+128.22%
KRYS Krystal Biotech	0.00%	-2.98%	-0.10%	-3.27%	+118.55%
KYMR Kymera Therapeutics	0.00%	+2.43%	-3.09%	+30.21%	+144.70%
QURE uniQure	0.00%	-1.15%	-10.00%	-4.95%	+210.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.64	Moderate Buy	$99.15	49.15% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	8.53% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$131.63	11.78% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	47.73% Upside

Current Analyst Ratings Breakdown

Latest QURE, KRYS, KYMR, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$123.00 ➝ $144.00
9/10/2026	KYMR Kymera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$180.00
9/8/2026	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$108.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	11.29	$0.12 per share	556.78	$3.64 per share	18.26
KRYS Krystal Biotech	$389.13M	25.61	$7.29 per share	46.18	$42.06 per share	8.00
KYMR Kymera Therapeutics	$39.21M	249.70	N/A	N/A	$19.42 per share	6.06
QURE uniQure	$16.10M	189.58	N/A	N/A	$3.19 per share	13.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	11/24/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	42.19	36.08	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest QURE, KRYS, KYMR, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
KRYS Krystal Biotech	N/A	8.32	7.96
KYMR Kymera Therapeutics	N/A	10.34	10.34
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KRYS Krystal Biotech	86.29%
KYMR Kymera Therapeutics	N/A
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
KRYS Krystal Biotech	13.10%
KYMR Kymera Therapeutics	15.98%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	711	140.86 million	135.79 million	Optionable
KRYS Krystal Biotech	295	29.60 million	25.72 million	Optionable
KYMR Kymera Therapeutics	273	83.15 million	69.86 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable

QURE, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

Engineers Gate Manager LP Sells 243,693 Shares of uniQure N.V. $QURE

September 15, 2026 | marketbeat.com

FDA expands Bayer lung cancer drug approval

September 10, 2026 | statnews.comS

What to expect from UniQure’s upcoming Huntington’s gene therapy readout

September 10, 2026 | statnews.comS

Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE

September 10, 2026 | marketbeat.com

uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?

September 8, 2026 | insidermonkey.com

uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP

September 7, 2026 | marketbeat.com

QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy

September 6, 2026 | ad-hoc-news.deA

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 5, 2026 | investorplace.com

uniQure (NASDAQ:QURE) Lowered to Sell Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

uniQure submits ifezuntirgene inilparvovec BLA to US FDA to treat Huntington’s disease

September 4, 2026 | pharmabiz.comP

uniQure files for US and UK approval for AMT-130 in Huntington’s disease

September 3, 2026 | thepharmaletter.comT

uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why

September 3, 2026 | marketbeat.com

QURE Submits Application for Gene Therapy for Huntington's Disease

September 3, 2026 | zacks.com

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 3, 2026 | investorplace.com

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

September 2, 2026 | biopharmadive.comB

UniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up

September 2, 2026 | rttnews.com

Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

September 2, 2026 | statnews.comS

uniQure Submits BLA for AMT-130 in Huntington's Disease

September 2, 2026 | finance.yahoo.com

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

September 2, 2026 | markets.businessinsider.com

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

September 2, 2026 | benzinga.com

15 Stocks to Watch With Short Squeeze Potential

September 2, 2026 | schaeffersresearch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$66.48 -1.26 (-1.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$66.97 +0.49 (+0.74%)

As of 09/18/2026 07:55 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Krystal Biotech NASDAQ:KRYS

$336.67 -2.08 (-0.61%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$340.88 +4.21 (+1.25%)

As of 09/18/2026 07:30 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Kymera Therapeutics NASDAQ:KYMR

$117.75 -0.73 (-0.62%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$117.75 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

uniQure NASDAQ:QURE

$44.00 -0.09 (-0.20%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.07 +0.07 (+0.16%)

As of 09/18/2026 07:30 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, KRYS, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, KRYS, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, KRYS, KYMR, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, KRYS, KYMR, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, KRYS, KYMR, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, KRYS, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Krystal Biotech NASDAQ:KRYS

Kymera Therapeutics NASDAQ:KYMR

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools